Retatrutide Black Market, Late 2026: Lawsuits, FDA Letters, Counterfeits

Retatrutide is not approved anywhere, yet it is one of the most widely self-administered investigational drugs in the world. Our own chatbot log reflects it: a large share of the questions we receive are from people who already have a vial and want to know how much to draw up. This article is about what happened to that market between late July and mid-September 2026, in four parts: Lilly’s lawsuits, the FDA’s warning letters, the first real-world data on grey-market users, and a counterfeit that hospitalised a patient in Australia.

The background is in our earlier explainer, Why You Can’t Safely Buy Retatrutide Online. This is the update.

1. Lilly sues six sellers and asks platforms and payment processors to act (August 12)

On August 12, 2026 Eli Lilly announced six federal lawsuits against businesses selling retatrutide in the United States:

• Aesthetic Envy Cosmetic Centers LLC, a med spa (Northern District of California)
• Astra LLC, trading as Astra Peptides (Western District of Texas)
• Legendary Peptides LLC (Eastern District of Texas)
• Striker Pharmacy LLC, a compounding pharmacy (Southern District of Texas)
• Texas Peptides Inc. (Western District of Texas)
• Lone Star Peptide Co. (Southern District of Texas)

Four are “research use only” peptide vendors, one is a med spa and one is a pharmacy, which covers the three channels through which most black-market retatrutide reaches patients. Lilly is seeking permanent injunctions and disgorgement of profits.

The numbers in the release describe the scale of the problem rather than the lawsuits: Lilly says it has reported more than 14,000 websites, advertisements, social-media posts and product listings in more than 100 countries and has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general and licensing boards. The company asked regulators to treat the trade as an urgent public-health matter, asked online platforms to block listings before they reach consumers, and asked payment and shipping companies to cut off the infrastructure the trade runs on. The public was asked to report illegal products to the Lilly Answers Center (1-800-LillyRx).

Lilly’s chief medical officer, David A. Hyman, put the company’s position in one sentence: “What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.”

Six lawsuits will not close a market of 14,000 listings. Their practical effect is to establish, in court, that selling a labelled-for-research peptide with instructions and dosing forums pointed at it is selling an unapproved drug, and to create a record that other sellers, platforms and payment processors can be held to.

2. FDA warning letters name “GLP-3 Reta” (August 24)

Twelve days later the FDA issued a set of warning letters to online peptide sellers, dated August 24, 2026 and posted in early September. The letter to Peptide Partners LLC of Sarasota, Florida, cites a product marketed as “GLP-3 Reta (Retatrutide)” alongside semaglutide, tirzepatide and other peptides, and charges the company with introducing unapproved new drugs into interstate commerce under sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act.

The sentence that matters for every “research use only” seller is this one: “Despite statements on your product labeling marketing your products ‘for research use only’… evidence obtained from your website establishes that your products are intended to be drugs for human use.” The FDA’s position is that the disclaimer does not change what the product is; the marketing does. The letter also notes that injectable products “pose risks of serious harm” because they bypass the body’s natural defences, and gives the company fifteen business days to respond with corrective actions.

Other sellers received letters in the same batch. The FDA has now sent warning letters to peptide vendors on several occasions since December 2024; what is new is the explicit naming of a retatrutide product and the timing, less than two weeks after Lilly’s lawsuits.

3. The first real-world data: grey-market users lose about half as much (preprint, August)

In late August a Massachusetts health-data company posted a preprint (not yet peer reviewed) analysing electronic health records that mentioned retatrutide. As reported by Medscape and Endpoints News, the analysis identified 652 patients with confirmed retatrutide exposure, of whom 71% were taking it outside a trial, mostly from online or telehealth sources and compounding pharmacies. Matched against trial participants, non-trial users lost 4.7%, 5.3% and 7.2% of body weight at 3, 6 and 12 months, against 5.7%, 11.9% and 15.5% for trial users, while showing the same heart-rate increase and a higher burden of cardiovascular symptoms. Non-trial use rose about 1.8-fold per quarter from late 2023 to early 2026.

This is a single preprint with a small trial comparison group, and the grey-market cohort is defined from clinical notes, so the figures should be read as an order of magnitude, not a measurement. But the direction is the one any pharmacologist would predict for a product of unknown identity, purity and concentration used without a titration protocol: the risks of the drug with a fraction of the benefit.

4. Australia: a “retatrutide” vial that was eight times a normal dose of semaglutide (September 14)

On September 14, 2026 Australia’s Therapeutic Goods Administration reported the result of testing a product sold as retatrutide after a patient was hospitalised. The vial contained no retatrutide at all. It contained semaglutide at roughly eight times the concentration found in the approved semaglutide products the TGA had assessed. The patient suffered uncontrollable vomiting that tore the oesophagus. The TGA’s chief medical adviser, Robyn Langham, summarised the problem: “the biggest risks with unapproved peptide products are not knowing what is in the vial, how much of, or even what substance it contains.”

This case answers a question people ask us often: “but what if the vendor’s certificate of analysis is real?” A certificate cannot protect against a vial that is a different drug. Substitution of a cheaper, more available peptide for a more expensive one is exactly what an unregulated supply chain rewards.

What this changes if you are thinking of buying

Nothing about the pharmacology has changed since our March explainer. What has changed is the enforcement environment and the evidence:

• Selling “research” retatrutide for human use is now being litigated as selling an unapproved drug, and payment processors and platforms are being asked directly to stop supporting it. Expect sellers to disappear, rebrand and reappear; a vendor that vanishes mid-course leaves the buyer with no continuity of supply and no recourse.
• The FDA has put retatrutide by name in warning letters and rejected the research-use-only defence in writing.
• The first outside-trial data, weak as it is, points to about half the weight loss with the same cardiovascular side effects.
• A regulator has documented a retatrutide product that was a dangerous dose of something else.

Retatrutide remains available only through clinical trials and, since August 2026, through Lilly’s narrow expanded access program for people with severe, refractory obesity. Lilly plans to file for approval in the first quarter of 2027, which puts the earliest realistic decision in late 2027. For most people the arithmetic has not moved: an approved drug now, or a trial, and retatrutide when it is a licensed medicine with a known content per vial.